Check 35,000+ stocks against 26 valuation models and 37 quality factors

Ping An Healthcare and Technology Company Ltd (1833) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Ping An Healthcare and Technology Company Ltd HK$3.15, price HK$6.35, upside -50.3%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG711391022

PA Thin data Oct 1, 2026

Ping An Healthcare and Technology Company Ltd

1833 · HK

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value HK$3.15 · Strongly overvalued (−50.3%)

!Quality 58/100

!Weak Growth (revenue 5y −4.5 %/yr)

!Thin margins · 8.5% net margin (TTM)

✓Low debt · generates free cash flow

!Mixed vs. peers (8/14)

!Narrow moat 33/100

!Evidence only low, so the estimate is less certain

!Weak on past: 19 out of 100

26 models, one by oneBear HK$2.52 to bull HK$4.06 Growth analysisrevenue history, year by year Quality 58/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Ping An Healthcare and Technology Company Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range HK$5.96 – HK$96.70 · fair‑value band HK$2.52 – HK$4.06 · the HK$6.35 price screens above the HK$3.15 fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow Ping An Healthcare and Technology Company in your weekly email

Every Wednesday you see whether Ping An Healthcare and Technology Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China.

Ping An Healthcare and Technology Company Limited, together with its subsidiaries, operates an online healthcare services platform in China. It offers online diagnosis and treatment, online consultation services, audio and video consultations, standardized healthcare service packages, health check-ups, genetic testing, concierge services, health management services, smart device sales, and consulting services. The company also provides online consultation, hospital referral and appointment, inpatient arrangement, and second opinion services; prepaid cards and health check-up services. The company online consultation, hospital referral, inpatient arrangement, second opinion services, electronic prescriptions, health management, prepaid packages for healthcare products and services, provision of products in the Group's health mall, advertising services, and consulting services, as well as operates an insurance agency. In addition it is involved in the integrated finance business. The company was incorporated in 2014 and is headquartered in Shanghai, China. Ping An Healthcare and Technology Company Limited operates as a subsidiary of Glorious Peace Limited.

Stock analysis

Ping An Healthcare and Technology Company Ltd (1833) currently trades at HK$6.35, while our model-based Fair Value estimate is HK$3.15, 50.3% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Dividend Discount group reads highest at a median of HK$26.74 per share, and 4 of the 26 models we run sit above the HK$6.35 price.

Bear case: the Economic Profit group reads lowest at HK$1.75, and 22 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$2.52 (bear) to HK$4.06 (bull), the price of HK$6.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Ping An Healthcare and Technology Company Ltd reported revenue of 5.5B CNY in FY2025 versus 7.3B CNY in FY2021, a compound −7.1%/yr. Reported net income was 380M CNY in FY2025.

Key figures

Market cap HK$13.5B (≈ $1.7B) · P/E ratio 25.4 · P/S ratio 1.76 · Net margin 6.9% · Return on equity 4.7% · Return on assets (EBIT) −3.3% · Operating margin 8.6% · Revenue (TTM) 5.4B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 66% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −50%, 1833 screens richer than that median.

Fair Value models

Bear HK$2.52 Fair Value HK$3.15 Bull HK$4.06

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$3.65 HK$5.32 HK$7.92 80

Growth DCF HK$3.61 HK$5.05 HK$7.15 79

5Y EBITDA Exit HK$2.74 HK$3.53 HK$4.49 77

All 26 models by family

DCF Models

FCF DCF HK$3.65 HK$5.32 HK$7.92 80

Owner Earnings HK$3.78 HK$5.54 HK$8.28 76

5Y Revenue Exit HK$2.47 HK$2.97 HK$3.59 74

5Y EBITDA Exit HK$2.74 HK$3.53 HK$4.49 77

5Y P/E Exit HK$4.17 HK$6.52 HK$9.26 70

10Y Revenue Exit HK$2.89 HK$3.50 HK$4.34 68

10Y EBITDA Exit HK$3.06 HK$3.88 HK$5.04 70

10Y P/E Exit HK$3.93 HK$5.90 HK$8.74 63

Earnings-Based

Graham-Dodd HK$1.42 HK$6.97 HK$9.61 64

Lynch FV HK$1.87 HK$2.68 HK$3.48 61

PEG = 1.0 HK$1.87 HK$2.68 HK$3.48 57

EPV HK$1.70 HK$1.75 HK$1.79 74

Dividend Discount

Gordon GGM HK$16.24 HK$29.27 HK$40.30 68

DDM Multi-Stage HK$16.24 HK$26.74 HK$31.27 67

Multiples

P/E Multiple HK$3.44 HK$4.59 HK$5.73 63

P/S Multiple HK$2.66 HK$3.54 HK$4.43 58

P/B Multiple HK$2.66 HK$3.54 HK$4.43 55

EV/EBIT HK$2.00 HK$2.22 HK$2.45 66

EV/EBITDA HK$2.29 HK$2.62 HK$2.95 67

EV/Revenue HK$1.80 HK$2.01 HK$2.22 54

Asset-Based

NCAV (Graham) HK$2.73 HK$3.65 HK$5.45 54

Growth DCF

Growth DCF HK$3.61 HK$5.05 HK$7.15 79

Rev-Margin DCF HK$2.47 HK$3.00 HK$3.69 74

Economic Profit

Residual Income HK$3.85 HK$3.79 HK$3.85 76

ROIC Compounder HK$1.70 HK$1.75 HK$1.79 72

Growth Earnings

Growth-Adj P/E HK$2.96 HK$4.23 HK$5.50 67

Open the full fair value analysis →

Notify me when 1833 reaches fair value

Put 1833 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 59 · Market factors (momentum, volatility) 18

Profitability 28

Margins and returns on capital today

Quality Growth 69

Are margins and returns improving?

Cashflow 53

Earnings quality: real cash, not paper profit

Fin. Strength 88

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 43

Calm price path (market factor)

Momentum 11

Price trend over the last 3–12 months (market factor)

52W Momentum 1

Distance to the 52-week high (market factor)

Net Issuance 23

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+13.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−4.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−4.5%

Start year 2020 (pandemic). Over 10 years: +34.7% a year

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+34.7%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−13.4% (2020) → 1.8% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year

not computed

Growth Forecast

Little optimism in the price

The price assumes more growth than the company has delivered so far and less than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+5.0%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+11.1%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +3.2% a year for the price and +9.2% for the forecasts.

Forecast 2026 (sales)+9.0%

Forecast 2027 (sales)+13.8%

Projected 2028 (sales)+12.4%

Projected 2029 (sales)+10.9%

Projected 2030 (sales)+9.4%

1833 screens overvalued: fair value 50% below the price. Compare with Veeva Systems Inc →

Compare Ping An Healthcare and Technology Company Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks

Beats the industry median on 8/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 58 · Above median

Fair Value upside −50.3% · Below median

Profitability

Return on equity (TTM) 4.7% · Above median

Return on assets 1.5% · Above median

Net margin (TTM) 8.5% · Above median

Operating margin (TTM) 8.6% · Above median

Growth and dividend

Revenue growth −0.7% · Below median

Balance sheet

Debt / equity 0.00× · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 25.4× · Cheaper than median

P/B 1.16× · Cheaper than median

P/S (TTM) 2.12× · Pricier than median

P/FCF 29.5× · Pricier than median

EV/EBITDA 27.1× · Priciest 25%

PEG 4.92× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)0 · sector 36

PAST (return on equity)19 · sector 7

HEALTH (low debt)100 · sector 98

DIVIDEND (yield)0 · sector 45

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$278.57	$306.43	+10%
Pro Medicus Limited PME	A$161.00	A$84.62	−47%
BrightSpring Health Services, Inc BTSG	$56.54	$25.86	−54%
Hinge Health, Inc HNGE	$95.57	$51.25	−46%
HealthEquity, Inc HQY	$88.44	$97.28	+10%
Waystar Holding WAY	$24.70	$27.17	+10%
Doximity, Inc DOCS	$26.35	$31.41	+19%
Inventurus Knowledge Solutions Limited IKS	₹1,779	₹1,883	+6%
Privia Health Group PRVA	$19.62	$5.02	−74%
Winning Health Technology Group 300253	¥6.98	¥3.44	−51%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ping An Healthcare and Technology Company Ltd · Fair Value
HK$3.15 −50%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/1833" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Ping An Healthcare and Technology Company Ltd · Fair Value</span><br><b style="font-size:20px">HK$3.15</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−50%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Ping An Healthcare and Technology Company Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1833

Frequently asked questions

Is Ping An Healthcare and Technology Company Ltd (1833) overvalued or undervalued?

As of Oct 1, 2026, our model estimates a fair value of HK$3.15 versus a price of HK$6.35, about −50% upside (overvalued).

What is the fair value of 1833?

Our model-based fair value for Ping An Healthcare and Technology Company Ltd is HK$3.15 (as of Oct 1, 2026), built from audited fundamentals. The current price: HK$6.35.

What is the quality score of 1833?

Ping An Healthcare and Technology Company Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Ping An Healthcare and Technology Company Ltd (1833)?

Our model-based price target is the fair value of HK$3.15 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario HK$2.52, optimistic scenario HK$4.06. It is a calculation from audited fundamentals, not an analyst target.

What is the Ping An Healthcare and Technology Company Ltd stock forecast for 2026?

Our models put fair value at HK$3.15, about −50% upside versus a price of HK$6.35 (overvalued). Cautious scenario HK$2.52, optimistic scenario HK$4.06. The calculation is refreshed regularly with new filings.

What is the revenue of Ping An Healthcare and Technology Company Ltd (1833)?

Ping An Healthcare and Technology Company Ltd reported trailing-twelve-month revenue of about 5.4B CNY (latest available figure, as of Oct 1, 2026).

What growth is priced into Ping An Healthcare and Technology Company Ltd (1833)?

For today's price to be fair in a discounted-cash-flow model, Ping An Healthcare and Technology Company Ltd would have to grow free cash flow by +5.0 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.5 % per year. As of Oct 1, 2026.

What discount rate (WACC) does the fair value of 1833 use?

Our models discount Ping An Healthcare and Technology Company Ltd at 12.1 %: a base by market capitalisation (small), damped by beta 1.12, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ping An Healthcare and Technology Company Ltd that is +5.0 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.

How much growth has Ping An Healthcare and Technology Company Ltd (1833) delivered so far?

Over the past 5 years revenue at Ping An Healthcare and Technology Company Ltd grew -4.5 % a year. The price currently implies +5.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Ping An Healthcare and Technology Company Ltd (1833) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Ping An Healthcare and Technology Company Ltd (+5.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Ping An Healthcare and Technology Company Ltd (1833)?

The free-cash-flow yield on the price is 3.39 %: that much free cash flow Ping An Healthcare and Technology Company Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Ping An Healthcare and Technology Company Ltd (1833)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ping An Healthcare and Technology Company Ltd it is HK$3.15 per share (as of Oct 1, 2026), against a price of HK$6.35. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Ping An Healthcare and Technology Company Ltd stock overvalued or undervalued in 2026?

As of Oct 1, 2026, 1833 trades above its calculated fair value: price HK$6.35, fair value HK$3.15, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 1833?

No. The price is what the market pays today (HK$6.35); the fair value is what the company's own numbers justify (HK$3.15). For Ping An Healthcare and Technology Company Ltd the two are HK$3.19 per share apart. That gap is exactly why we show both numbers side by side.

How much is Ping An Healthcare and Technology Company Ltd worth?

The market values Ping An Healthcare and Technology Company Ltd at about HK$13.5B (market capitalisation, as of Oct 1, 2026). Per share that is HK$6.35; our models calculate a fair value of HK$3.15 per share.

What do the bullish and bearish scenarios say about 1833?

Our models span a range for Ping An Healthcare and Technology Company Ltd: cautious scenario HK$2.52, base HK$3.15, optimistic HK$4.06 per share (as of Oct 1, 2026, price HK$6.35). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 1833?

Ping An Healthcare and Technology Company Ltd trades at a price-to-earnings ratio of 25.4 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.15 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 27.0 (reported for FY2025: 30.5). Other multiples: PEG 4.9, P/B 1.2, P/S 2.1, EV/EBITDA 27.1.

What is the PEG ratio of 1833?

The PEG ratio of Ping An Healthcare and Technology Company Ltd is 4.92 (P/E divided by earnings growth, as of Oct 1, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of Ping An Healthcare and Technology Company Ltd (1833)?

Balance-sheet figures for Ping An Healthcare and Technology Company Ltd (as of Oct 1, 2026): return on equity 4.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.

How far is 1833 from its 52-week high?

Ping An Healthcare and Technology Company Ltd trades at HK$6.35, about 66% below its 52-week high of HK$18.53 and 6% above the low of HK$5.96 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.15 is for.

Which stocks are comparable to Ping An Healthcare and Technology Company Ltd?

From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Ping An Healthcare and Technology Company Ltd stock attractive at the current price?

The data as of Oct 1, 2026: price HK$6.35, calculated fair value HK$3.15 (−50%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 1833 calculated?

We run Ping An Healthcare and Technology Company Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$3.15, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Ping An Healthcare and Technology Company Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Ping An Healthcare and Technology Company Ltd (1833)?

The closing price on Sep 30, 2026 was HK$6.35. Our model-based fair value is HK$3.15, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Ping An Healthcare and Technology Company Ltd right now?

The price sits above even our optimistic bull case (HK$4.06). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Ping An Healthcare and Technology Company Ltd

How large is the market capitalisation of Ping An Healthcare and Technology Company Ltd (1833)?

The market capitalisation of Ping An Healthcare and Technology Company Ltd is HK$13.5B (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Ping An Healthcare and Technology Company Ltd (1833)?

The price-to-sales ratio of Ping An Healthcare and Technology Company Ltd is 1.76 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of Ping An Healthcare and Technology Company Ltd (1833)?

The net margin of Ping An Healthcare and Technology Company Ltd is 6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Ping An Healthcare and Technology Company Ltd (1833)?

The return on equity (ROE) of Ping An Healthcare and Technology Company Ltd is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Ping An Healthcare and Technology Company Ltd (1833)?

On an EBIT basis the return on assets of Ping An Healthcare and Technology Company Ltd is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Ping An Healthcare and Technology Company Ltd (1833)?

The operating margin of Ping An Healthcare and Technology Company Ltd is 8.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Ping An Healthcare and Technology Company Ltd (1833)?

Revenue at Ping An Healthcare and Technology Company Ltd is growing −0.7% versus a year earlier (3y avg −4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Ping An Healthcare and Technology Company Ltd (1833)?

Earnings per share at Ping An Healthcare and Technology Company Ltd are growing +48.2% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Ping An Healthcare and Technology Company Ltd (1833) hold?

Ping An Healthcare and Technology Company Ltd holds more cash than debt, 2.4B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Ping An Healthcare and Technology Company Ltd in the live analysis

One click puts Ping An Healthcare and Technology Company Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.